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DEL red blood cells (RBCs) type as D– by routine serologic 
methods and are transfused routinely, without being identified as 
expressing a very weak D antigen, to D– recipients. DEL RBCs are 
detected only by adsorption and elution of anti-D or by molecular 
methods. Most DEL phenotypes have been reported in population 
studies conducted in East Asia, although DEL phenotypes have 
been detected also among Caucasian individuals. Approximately 
98 percent of DEL phenotypes in East Asians are associated with 
the RHD*DEL1 or RHD*01EL.01 allele. The prevalence of DEL 
phenotypes has been reported among D– Han Chinese (30%), 
Japanese (28%), and Korean (17%) populations. The prevalence 
of DEL phenotypes is significantly lower among D– Caucasian 
populations (0.1%). Among the 3–5 percent of African individuals 
who are D–, there are no reports of the DEL phenotype. Case 
reports from East Asia indicate that transfusion of DEL RBCs 
to D– recipients has been associated with D alloimmunization. 
East Asian immigrants constitute 2.1 percent of the 318.9 million 
persons residing in the United States, and an estimated 2.8 
percent are blood donors. Using these statistics, we estimate that 
68–683 units of DEL RBCs from donors of East Asian ancestry 
are transfused as D– annually in the United States. Given 
the reports from East Asia of D alloimmunization attributed 
to transfusion of DEL RBCs, one would expect an occasional 
report of D alloimmunization in the United States following 
transfusion of DEL RBCs to a D– recipient. If such cases do occur, 
the most likely reason that they are not detected is the absence 
of active post-transfusion monitoring for formation of anti-D. 
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In 1984, Okubo and colleagues at the Osaka Red Cross 
Blood Center reported their observation that “some D-negative 
red cells, though they were negative in a Du test after exposure 
to anti-D, could bind anti-D and yield it on elution.”1 They 
named the phenotype of these red blood cells (RBCs) Del (D 
eluate), adding that “most phenotypes with Del had C, c, and e 
antigens, but no cells of an EE homozygote have yet adsorbed 
anti-D.”2 During the subsequent 30 years, these observations 
have been confirmed by several investigators. The Del 
phenotype has been renamed DEL and is, in D– East Asians, 
predominantly caused by the RHD(1227G>A) allele, which has 
since been termed RHD*DEL1 or RHD*01EL.01 (International 
Society of Blood Transfusion [ISBT] terminology). This review 
summarizes the current status of molecular science and 
demographic distribution of the DEL phenotype.
Molecular Investigations of DEL Phenotypes
In 1997, investigators at the Osaka Red Cross Blood Center 
reported that polymerase chain reaction with sequence-specific 
primers (PCR-SSP) for RHD exons 7, 4, and 10 detected PCR 
products in all 102 DEL blood samples, but not in 204 non-
DEL samples from D-seronegative donors.3 Among a total of 
306 D– donor samples, Fukumori and colleagues found 102 
donors with the DEL phenotype associated with CCee (4 of 5), 
CcEe (45 of 66), and Ccee (53 of 86). No DEL phenotypes were 
detected among D– samples that were ccee—that is, none were 
C+ or E+.3 The authors concluded that DEL RBCs have exons 
4, 7, and 10 of RHD present in some form. In 2001, three DEL 
alleles were characterized in German blood donors by Wagner 
and coworkers.4 One of the alleles, RHD(K409K) (G1227A) or 
RHD*DEL1, was soon shown to be prevalent among D– East 
Asians5 and later termed “Asia type DEL” by Shao et al.6 Also, 
in 2001, Singleton and colleagues described in abstract form 
the partial nucleotide sequences for the alleles IVS1+1A and 
G1227A in three Japanese donors with the DEL phenotype,7 
a terminology consistent with Human Genome Variation 
Society nomenclature.8
In 2004, J.-C. Chen and colleagues reported detection of 
RHD*DEL1 in all (100%) of 94 D– Taiwanese blood donors.9 
Additional DEL variants were reported in blood donors in 
Germany4 and in China.10 The report of genomic deletion of 
RHD exon 9 by Chang et al. in 199811 has not been confirmed 
and is not considered to be an established basis for any DEL 
phenotype.12 Instead, RHD*DEL1 is the result of a single 
nucleotide polymorphism in a splice-site on exon 9 that leads 
to reduced D antigenic density, but may retain the intact D pro-
tein.12 This mechanism has been well studied for RHD*DEL1, 
in which a “silent” 1227G>A substitution in RHD codon 409 
is immediately adjacent to the exon 9/intron 9 boundary.13 
To emphasize the structural basis of the (unchanged) 
protein, a novelty at the time, this allele was originally called 
RHD(K409K).4 Later, the term RHD(1227G>A), based on the 
allele’s nucleotide structure, became more widely used13 and, 
presently, updated to RHD*DEL1 by ISBT nomenclature.
To date, investigators have identified more than 40 alleles 
that are associated with a DEL phenotype.14 The RHD*DEL1 
allele,4 which accounts for up to 98 percent of DEL phenotypes 
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in East Asians,15,16 is the most prevalent variant RHD allele in 
the D– East Asian population. For consistency, we will use 
RHD*DEL1 for the “Asia type DEL” allele for the remainder of 
this review.
DEL Phenotype in East Asian Populations
The RHD*DEL1, or as in the original report, RHD(K409K), 
allele4 is the most prevalent variant RHD allele in D– East 
Asian populations,5 and RHD*DEL2 (RHD 3G>A) was thought 
to be the second most common DEL allele, at least in Chinese 
populations.17 Ji and van der Schoot observed that RHD*DEL1 
was the most common DEL allele among D– Han Chinese 
in the southern region of China.18 The prevalence of DEL 
phenotypes among the 0.3–0.5 percent of Han Chinese who 
are D–19,20 is 30 percent for native Chinese15 and 32 percent 
for those living in Taiwan.9 Among Japanese, 0.5 percent are 
D–,2 and of these, 28 percent express a DEL phenotype.21 In 
Korean populations, 0.15 percent are D–, and of these, 17 
percent express a DEL phenotype.12,22,23 The prevalence of DEL 
phenotypes is significantly lower in Caucasian populations, of 
whom approximately 15 percent are D– and only 0.1 percent 
of these express a DEL phenotype.24 Among the 3–5 percent of 
African populations who are D–,25 there are no reports of DEL 
phenotypes, but few population studies have been conducted.
DEL Phenotype in Caucasian Populations
More than 40 DEL alleles are currently listed in the human 
RhesusBase,14 and all belong in the Eurasian D cluster.26 Most 
of these DEL alleles have been reported as individual cases in 
Caucasian populations. Except for RHD*DEL1, all DEL alleles 
are rare in any population, particularly in Caucasian and 
African populations. The cumulative prevalence of all DEL 
phenotypes that are associated with DEL alleles, other than 
RHD*DEL1, is small in any population when compared with 
the prevalence of DEL phenotypes associated with RHD*DEL1 
in East Asian populations. Although other rare DEL alleles add 
to the risk of D alloimmunization, we conclude that the overall 
risk of D alloimmunization in the United States is defined by 
the prevalence of RHD*DEL1.
Transfusion of DEL RBCs to D– Recipients 
Has Been Associated with Secondary D 
Alloimmunization and May Be Associated with 
Primary D Alloimmunization
Recognizing the very weak serologic expression of D by 
DEL phenotype RBCs, early investigators considered it unlikely 
that RBCs expressing a DEL phenotype would elicit D allo-
immunization.27 Subsequently, cases of D alloimmunization 
by DEL RBCs have been reported. In 2005, T. Wagner et al. 
proposed D alloimmunization in a D– female patient after she 
had been transfused with RBCs from an Austrian donor who 
tested D– and weak D test negative by serologic methods.28 
The authors identified a deletion in the donor’s RHD that they 
described as “RHD IVS5-38del4” and linked it to expression 
of the DEL phenotype.28 Subsequent studies determined that 
the deletion IVS5-38del4 does not cause a DEL phenotype and 
is common in European and Asian populations.29 The cause 
of a DEL phenotype in the implicated Austrian blood donor 
remains unknown, and the deletion presently designated as 
RHD(IVS5-38del4) is thought to be unrelated.29
In 2005, Yasuda et al. described a D– Japanese woman 
who developed a secondary D alloimmunization after 
transfusion with 2 units of RBCs that were subsequently 
determined to be from Japanese donors with the RHD*DEL1 
allele.30 In 2009, K. Kim et al. described a D– Korean man who 
developed anti-D 9 days after transfusion with 1 unit of RBCs 
that was subsequently determined to express the RHD*DEL1 
allele.23 
In 2012, Shao et al. described one case of primary immune 
response and two cases of secondary immune responses 
in a total of 11 recipients in central China who had been 
transfused with RBCs from DEL phenotype donors with the 
RHD*DEL1 allele.15 This study of 11 recipients included seven 
pre-transfusion anti-D–negative patients, who were at risk 
for a primary immune response following transfusion of DEL 
RBCs, and four pre-transfusion anti-D–positive patients. One 
of the seven at-risk recipients, who tested negative for anti-D 
on admission and had no transfusion history, was transfused 
twice with DEL RBCs. On day 22 after the first transfusion, 
he formed anti-D (titer 2), which the authors interpreted to be 
“characteristic of primary anti-D alloimmunization.” Two of 
the four anti-D–positive recipients demonstrated a 50 percent 
increase in anti-D titer after the transfusion, describing 
secondary immune response. The authors concluded “that 
blood centers and blood banks need to identify the presence 
of the DEL variant in apparent D-negative donors and 
recipients. A truly D-negative recipient should not receive DEL 
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transfusion in an effort to protect him or her from primary 
alloimmunization or severe DHTR.”15 
In 2015, H.S. Yang et al. reported detection of anti-D 
between days 5 and 7 after transfusion of 2 units of RBCs from 
Korean donors to a Caucasian male patient.16 Retrospective 
studies of RBCs from the Korean donors confirmed that the 
donors’ RBCs tested as D– by serologic anti-D and weak D 
testing. RHD genotyping identified the RHD*DEL1 allele in 
both donors.16 The short time interval between transfusions 
and detection of anti-D in the recipient suggests that these 
events were more likely secondary immune responses.
Transfusion Recipients with a DEL Phenotype and 
an RHD*DEL1 Allele Are Not at Risk of Forming 
Anti-D Following Transfusion of D+ RBCs
In 2005, Körmöczi and colleagues proposed that the 
absence of D alloimmunization by transfusion recipients with 
a DEL phenotype following transfusion of D+ RBCs was 
explained by serologic studies showing that the RHD*DEL1 
allele expresses a complete repertoire of D epitopes.31 In 2006, 
Flegel suggested that East Asians expressing a DEL phenotype 
and carrying the RHD*DEL1 allele might not form anti-D after 
exposure to D+ RBCs.32 The extremely weak expression of D 
by serologic testing is caused by significantly fewer D antigen 
sites per RBC (<22) compared with normal RBCs (CcDdee with 
10,429) and weak D phenotypes (922).31 In 2014, Q.P. Wang 
et al. conducted a retrospective study of 227 D– transfusion 
recipients in southeast China who had been transfused with 
RBCs, presumably some of which were D+.33 Eleven recipients 
developed anti-D. None of the transfusion recipients with 
anti-D had a DEL phenotype associated with the RHD*DEL1 
allele. The time interval between transfusions and testing for 
anti-D was not specified. Wang et al. concluded that “people 
in East Asian populations who carry Del variants can safely 
receive transfusions from RhD-positive donors. Our findings 
would apply to East Asian transfusion recipients in Europe, 
North America, and elsewhere and could be implemented 
easily when genetic crossmatching becomes a reality.”33 
Pregnant Women with a DEL Phenotype Who 
Delivered a D+ Newborn Did Not Form Anti-D, But 
Pregnant Women with Certain Partial or Hybrid 
DEL Alleles Have Formed Anti-D
In 2010, Shao et al. reported a retrospective study of 
104 D– pregnant Chinese women who formed anti-D after 
delivery.10 Based on the prevalence of DEL phenotypes in the 
local Han Chinese population, these investigators anticipated 
that 30 percent of the women who formed anti-D would have a 
DEL phenotype, but none did (0%).10 In the same report, Shao 
et al. described a prospective study of 44 pregnant women 
with the DEL phenotype who did not receive Rh immune 
globulin (RhIG) immunoprophylaxis and did not form 
anti-D. During the 2-year study period, 38 of 155 (24.5%) 
D– (dccee) mothers formed anti-D. The authors concluded 
that women with RHD*DEL1 do not appear to be at risk of 
alloimmunization to the D antigen and “DEL recipients can be 
transfused safely with Rh-positive blood.”10 The authors also 
concluded that RhIG prophylaxis is unnecessary (in women 
with an RHD*DEL1 allele).10 
In 2014, Q.P. Wang et al. studied D alloimmunization in 416 
D– pregnant women. Anti-D was detected in 61 of these 416 
D– pregnant women (14.66%) and in 11 of 227 D– transfusion 
recipients (4.85%). None of the 72 D– pregnant women or 
transfusion recipients with anti-D had a DEL phenotype. The 
time interval from delivery to follow-up was not reported. 
The authors concluded that antenatal and postpartum Rh 
immunoprophylaxis with RhIG was unnecessary in pregnant 
women with a DEL phenotype.33 In 2015, M. Wang et al. 
described the outcome of 142 pregnant Han Chinese women 
with a DEL phenotype who delivered a D+ newborn.34 None of 
130 women (0%) with a DEL phenotype caused by RHD*DEL1 
formed anti-D. There were six women with a DEL phenotype 
who formed anti-D after delivery. All six of these women had 
a DEL phenotype associated with RHD-CE-D hybrid alleles34 
encoded by RHD exons replaced by counterparts from RHCE 
genes, with a resultant loss of one or more D epitopes.4 The 
authors cite the proposal by Körmöczi and colleagues31 for 
defining partial DEL phenotypes by drawing an analogy with 
the definition for partial D variant antigens (i.e., an RHD/RHCE 
gene recombination event that affects exofacial D sections and 
loss of one or more D epitopes). Thus, M. Wang et al. refer to 
DEL antigens resulting from these recombinations as partial 
DEL phenotypes and concluded that “individuals with a partial 
DEL phenotype should be treated as RhD-negative...and receive 
only RhD-negative RBCs.” Also, “pregnant women [with a 
partial DEL phenotype] should be administered antenatal 
and postpartum anti-D prophylaxis, whereas patients with a 
complete DEL type can safely receive RhD-positive blood...and 
do not need RhD immunoglobulin prophylaxis.”34 
In 2015, Xu et al. reported the outcomes of 168 pregnant 
Chinese women with a DEL phenotype of the RHD*DEL1 
allele and 8 women with the RHD(3G>A) allele who delivered a 
D+ newborn.35 None developed anti-D. Two pregnant women 
with a DEL phenotype and the RHD-CE(4-9)-D or RHD-
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CE(2-5)-D allele did form anti-D; one was associated with 
mild hemolytic disease of the fetus and newborn (HDFN). 
The authors concluded that the observation of anti-D in the 
two women with absent D epitopes confirms that their RBCs 
express partial DEL phenotypes and pregnant women with 
these alleles are at risk for forming anti-D.35 
Within Caucasian populations, there are DEL phenotypes 
arising from changes at the intron exon splice boundaries;4 at 
least one of these has been associated with anti-D and another 
has been associated with mild HDFN.36
DEL Phenotype Is Associated with the C Blood 
Group Antigen
The association of the DEL phenotype and the C antigen, 
first described by Okubo et al. in 1984,1 has been confirmed 
by subsequent studies and provides a promising strategy for 
a low-cost, efficient method to screen large numbers of donors 
for DEL phenotypes. RBCs from as many as 18 percent of D– 
Japanese donors express C,21 whereas only 1 in 1818 (0.055%) 
RBCs from D– Caucasian donors express C.4 A 6-year study 
of D– European individuals demonstrated that the prevalence 
of the DEL phenotype is much higher among D– blood donors 
whose RBCs express C and/or E, concluding that the DEL 
phenotype was associated with a Cde or cdE haplotype.14 
The longstanding observations that the presence of Ce in cis 
with a variant RHD allele had a suppressive effect resulting 
in a DEL-like phenotype further strengthens the apparent 
relationship between C and the DEL phenotype.1 D– East 
Asian populations have a high association of RHD*DEL1 with 
C (99–100%), as originally observed among five individuals,4 
because RHD*DEL1 is linked to an RHCE*Ce allele in one 
haplotype (in cis configuration on one chromosome).
The association with the E antigen (i.e., an RHCE*cE allele 
in trans) shows considerable ethnic variability. The association 
with E in Chinese and Taiwanese individuals is 3.7 and 2.6 
percent, respectively, whereas the association in Korean and 
Japanese individuals is 28.6 and 38.4 percent, respectively 
(Table 1). This variation in linkage has resulted in different 
proposals for managing clinical aspects of the DEL phenotype. 
Y.H. Wang et al. proposed screening for the DEL phenotype 
by testing RBCs from apparent D– donors for C, followed by 
genotyping for RHD*DEL1.37 Seo et al. demonstrated that 
RBCs testing negative for C and E by serology safely predicts 
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Table 1. RHCE predicted genotypes in East Asians associated with the RHD*DEL1 allele
Reference Country
Number of individuals Association  
with Cc or CC
(%)
Association  
with Ee or EE
(%)Ccee CCee CeEe CCEe ccEe CcEE ccEE ccee
J.-C. Chen et al. (2004)9 Taiwan
N = 94
78 14 1 1 0 NA NA NA 100 2.6
Luettringhaus et al. (2006)12 Korea
N = 16
15 NA 1 NA NA NA NA NA 100 6.3
Q.P. Wang et al. (2014)33 China
N = 151
85 66 NA NA NA NA NA NA 100 0
Xu et al. (2015)35 China
N = 168
150 10 2 4 2 NA NA NA 98.8 4.8
Y.H. Wang et al. (2005)37 China
N = 126
105 18 2 1 NA NA NA NA 100 2.4
Seo et al. (2016)38 Korea
N = 14
7 3 4 NA NA NA NA NA 100 28.6
Ogasawara et al. (2015)39 Japan
N = 318
166 30 121 1 NA NA NA NA 100 38.4
Gu et al. (2014)40 China
N = 37
32 3 1 1 NA NA NA NA 100 5.4
Q. Li et al. (2008)41 Chinese 
minority
N = 14
12 1 1 NA NA NA NA NA 100 7.1
J.J. Wu et al. (2006)42 China
N = 41
32 8 1 NA NA NA NA NA 100 2.4
Total (N = 979) 682 153 134 8 2 0 0 0
(%) 69.7 15.6 13.7 0.8 0.2 0 0 0
NA = not applicable.
IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017 129
true D– RBCs (100% positive predictive value) (N = 4407), 
and RBCs testing negative by anti-D, but testing C+ and/or 
E+ by serology, can be tested for DEL by RHD genotyping, 
including promoter, intron 4, exon 7, and exon 10.38 In 1984, 
Okubo et al. considered the possibility that the specificity of 
the antibody formed by D– individuals exposed to D–, C+ 
RBCs could be anti-G. They excluded anti-G, confirming the 
serologic anti-D specificity using rG-reagent RBCs.1 In 2005, 
Yasuda and colleagues also considered the possibility that the 
specificity of the antibody formed when D– individuals were 
exposed to DEL RBCs that were D–, C+ could be anti-G.30 
They excluded anti-G and confirmed anti-D specificity by 
adsorption and elution studies.
Potential Risk of D Alloimmunization by 
Transfusion of DEL RBCs with an RHD*DEL1 Allele 
in the United States
There are inadequate data on the number of East Asian 
and other blood donors in the United States for an accurate 
calculation of the risk of D alloimmunization in D– recipients 
who are transfused, unknowingly, with DEL RBCs. There are 
data, however, that make it possible to calculate a reasonable 
range (maximum and minimum estimates). East Asians 
constitute 2.2 percent of 318.9 million people residing in the 
United States (4.01 million Chinese, 1.71 million Korean, and 
1.3 million Japanese).43 The prevalence of D– phenotypes 
in East Asians ranges from 0.1 to 0.5 percent,1,10,27 although 
the genotypic prevalence may be increased to 1 percent if 
mixed ethnic populations in the United Stated are considered. 
The percent of DEL phenotypes among D– East Asians is 
approximately 17.7 percent based on population surveys (Table 
2; 2047 individuals with the RHD*DEL1 allele among 11,592 
D– individuals surveyed translates to a prevalence of 17.7%). 
According to a multi-institution 10-year study, 2.8 percent of 
blood donors were Asians on average.48 Using these data, we 
estimate that 68–683 units of “Asian-type” (RHD*DEL1)- 
DEL RBCs are transfused annually in the United States 
(Table 3). Yazer et al. emphasized the importance of minority 
donor recruitment and collection programs to maintain an 
adequate blood supply in response to the diversity of the U.S. 
population.48,49
DEL phenotype
Table 2. RHD*DEL1 allele in serologic D– East Asian populations
Reference Country Subjects (N) Subject type
RHD(1227G>A)
n (%)
J.-C. Chen et al. (2004)9 Taiwan 294 Blood donor 94 (32.0)
Luettringhaus et al. (2006)12 Korea 126 Blood donor 16 (12.7)
Q. Li et al. (2009)17 China 1585 Blood donor 268 (16.9)
Y.E. Yang et al. (2007)20 Han Chinese living in Taiwan 294 Blood donor 108 (36.7)
Y.J. Kim et al. (2005)22 Korea 264 Blood donor 43 (16.3)
Yasuda et al. (2005)30 Japan 57 Blood donor 2 (3.5)






Xu et al. (2015)35 China 808 Pregnant woman 168 (20.8)
Y.H. Wang et al. (2005)37 China 395 Blood donor 126 (31.9)
Seo et al. (2016)38 Korea 110 Blood donor 14 (12.7)
Ogasawara et al. (2015)39 Japan 3526 Blood donor 318 (9.0)
Gu et al. (2014)40 China 165 Blood donor 37 (22.4)
Q. Li et al. (2008)41 Chinese minority 150 Blood donor 14 (9.3)
J.J. Wu et al. (2006)42 China 143 Blood donor 41 (28.7)
X. Wu et al. (2014)44 China 2385 Blood donor 516 (21.6)
J.H. Li et al. (2012)45 China 374 Blood donor 61 (16.3)
Q. Chen et al. (2012)46 China 155 Blood donor 32 (20.6)
Sun et al. (2008)47 Taiwan 118 Blood donor 38 (32.2)
Total 11,592 2047 (17.7)
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Discussion
Considering the number of DEL RBCs that are transfused 
in the United States annually, one may ask, “Where are these 
transfusion recipients with D alloimmunization in the United 
States?” and “Why has DEL-related D alloimmunization 
been reported only in East Asia, but not in the United States 
and elsewhere?” The same questions can be asked about any 
infrequent outcome of blood transfusion for which there is 
no active monitoring. Without active and timely follow-up 
for formation of anti-D by D– transfusion recipients, it is not 
possible to determine the true risk of D alloimmunization.50 
DEL-related D alloimmunization is another example of 
an infrequent, but potentially adverse, outcome of blood 
transfusion that is not recognized because it is not actively 
monitored. 
One option for addressing the potential risk that DEL 
RBCs may pose to D– transfusion recipients in the United 
States would be to initiate active post-transfusion monitoring 
for formation of anti-D. The intent would be to identify the 
incidence of D alloimmunization by documenting the number 
of DEL units of RBCs transfused in the United States and 
the number of D– patients who form anti-D after an RBC 
transfusion. Such an approach, however, would result in 
continued exposure of D– women and others to the risks of 
D alloimmunization. The delay in addressing measures to 
prevent transfusion of DEL phenotype RBCs to D– recipients 
should raise ethical questions. 
An alternative and more timely resolution would be to 
follow the model of the German Red Cross Blood Donor 
Service in Baden-Württemberg-Hessen and begin testing 
donated blood to exclude RBC units with a DEL phenotype 
in one or more blood centers in communities with a sizeable 
East Asian population.12 Beginning in 2002, blood samples 
from serologically D– first-time blood donors in Baden-
Württemberg-Hessen were tested by RHD PCR in pools of 
20. Samples detected to contain RHD were further tested by 
PCR and nucleotide sequencing to identify the specific RHD 
allele. That program cost approximately $5 per first-time D– 
donor, or $0.08 per unit of whole blood.24 Similar approaches 
are routine at the National Institutes of Health Blood Bank in 
the Department of Transfusion Medicine since 2009 and at 
the Swiss Red Cross Blood Service since 2013. Alternatively, 
the cost of identifying most Asian-type DEL units could be 
reduced by serologic screening of D– units for C and, possibly, 
E. This approach is based on the finding that DEL phenotypes 
occur when linked to the Ce allele or, less frequently, if at all, 
to the cE allele. This screening could be performed by PCR, 
or even less expensively, by testing with anti-C and, possibly, 
anti-E using an automated blood typing analyzer. In all 
scenarios, units of D– RBCs detected to contain an RHD allele, 
or a C or E antigen, would be added to the D+ inventory. In 
2005, Garratty noted that the DEL phenotype was usually 
associated with D–, C+ phenotypes and questioned whether 
we need to be more concerned about weak D antigens.51 In 
2008, Denomme and Flegel identified numerous opportunities 
for integrating advances in molecular immunohematology, 
including screening for low-copy number of D antigens (e.g., 
weak D or DEL) into routine transfusion practice.52 
Considering the multiple case reports of DEL-related D 
alloimmunization in Asian countries, and recognizing the 
significant number of blood donors of Asian descent in the 
United States, it is imperative to analyze the risk of transfusing 
DEL RBCs to D– recipients in the United States. If there is 
a confirmed risk, it is critical to develop a timely strategy to 
reduce the risk to D– transfusion recipients and, most urgently, 
to all female patients of child-bearing potential.
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Table 3. Estimated number of RBC units with the RHD*DEL1 allele transfused per year in the United States
Calculation
RBC units transfused  
per year (N)
Asians in the U.S.  
(2.8% of the donor population)
Prevalence of D– phenotype in  
East Asians (0.1–1%)
Prevalence of RHD*DEL1 allele  
in D– East Asians (17.7%)
RBC units with DEL phenotype  
(N)
Estimate
Minimum 13,785,000 × 0.028 × 0.001 × 0.177 68
Maximum 13,785,000 × 0.028 × 0.01 × 0.177 683
RBC = red blood cell.
IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017 131
views expressed do not necessarily represent the view of the 
National Institutes of Health, the Department of Health and 
Human Services, or the U.S. Federal Government.
Conflict of Interest
DHK and SGS declare having no conflicts of interest 
relevant to this article. WAF receives royalties for RHD 
genotyping.
References
 1. Okubo Y, Yamaguchi H, Tomita T, Nagao N. A D variant, Del? 
Transfusion 1984;24:542.
 2. Okubo Y, Seno T, Yamano H, et al. Partial D antigens disclosed 
by a monoclonal anti-D in Japanese blood donors. Transfusion 
1991;31:782.
 3. Fukumori Y, Hori Y, Ohnoki, et al. Further analysis of Del 
(D-elute) using polymerase chain reaction (PCR) with RHD 
gene-specific primers. Transfus Med 1997;7:227–31.
 4. Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes 
in D negative Europeans. BMC Genet 2001;2:10.
 5. Shao CP, Maas JH, Su YQ, et al. Molecular background of 
Rh D-positive, D-negative, D(el) and weak D phenotypes in 
Chinese. Vox Sang 2002;83:156–61.
 6. Shao CP. Transfusion of RhD-positive blood in “Asia type” DEL 
recipients. N Engl J Med 2010;362:472–3.
 7. Singleton BK, Green CA, Kimura K, et al. Two new RHD 
mutations associated with the Del phenotype (abstract). 
Transfus Clin Biol 2001;8(Suppl 1):9s.
 8. Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS 
recommendations for the description of sequence variants: 
2016 Update. Human Mutat 2016;37:564–9.
 9. Chen J-C, Lin T-M, Chen YI, et al. RHD 1227A is an important 
genetic marker for RhDel individuals. Am J Clin Pathol 
2004;122:193–8.
 10. Shao CP, Xu H, Xu Q, et al. Antenatal Rh prophylaxis is 
unnecessary for “Asia type” DEL women. Transfus Clin Biol 
2010;17:260–4.
 11. Chang JG, Wang JC, Yang TY, et al. Human RhD el is caused 
by a deletion of 1013 bp between introns 8 and 9 including 
exon 9 of RHD gene (letter). Blood 1998;92:2602–4.
 12. Luettringhaus TA, Cho D, Ryang DW, Flegel WA. An easy 
RHD genotyping strategy for D– East Asian persons applied 
to Korean blood donors. Transfusion 2006;46:2128–37.
 13. Wagner FF. RHD PCR of D-negative blood donors. Transfus 
Med Hemother 2013;40:172–81.
 14. Wagner FF, Flegel WA. The rhesus site. Transfus Med 
Hemother 2014;41357–63. (The human RhesusBase, version 
2.0. http://www.rhesusbase.info/, update 2017-02-19.)
 15. Shao C, Wang B, Ye S, et al. DEL RBC transfusion should 
be avoided in particular blood recipient in East Asia due to 
allosensitization and ineffectiveness. J Zhejiang Univ Sci B 
2012;13:913–8.
 16. Yang HS, Lee MY, Park TS, et al. Primary anti-D 
alloimmunization induced by “Asian type” RHD (C.1227G>A) 
DEL red cell transfusion. Ann Lab Med 2015;35:554–6.
DEL phenotype
 17. Li Q, Hou L, Ye LY, et al. Molecular basis of the RHD gene in 
blood donors with DEL phenotypes in Shanghai. Vox Sang 
2009;97:139–46.
 18. Ji YL, Van der Schoot CE. Red blood cell genotyping in China. 
ISBT Sci Ser 2016;11:55–68.
 19. Gu J, Wang X, Shao C, et al. Molecular basis of DEL phenotype 
in the Chinese population. BMC Med Gen 2014;15:54.
 20. Yang YE, Wang YH, Chen JC, et al. Prevalence of RHD1227A 
and hybrid rhesus in the general Chinese population. Translat 
Res 2007;149:31–6.
 21. Okuda H, Kawano M, Iwamoto S, et al. The RHD gene is highly 
detectable in RhD-negative Japanese donors. J Clin Invest 
1997;100:373–9.
 22. Kim YJ, Kim YS, Kim C, et al. Molecular characterization of 
D– Korean persons; development of a diagnostic strategy. 
Transfusion 2005;45:345–52.
 23. Kim K, Kim K, Wook K, et al. Primary anti-D immunization by 
DEL red blood cells. Korean J Lab Med 2009;29:361–5.
 24. Flegel WA, Zabern IV, Wagner FF. Six years’ experience 
performing RHD genotyping to confirm D– red blood cell units 
in Germany for preventing anti-D immunizations. Transfusion 
2009;49:465–71.
 25. Daniels G. Human blood groups. 2nd ed. Malden, MA: 
Blackwell Science, 2002.
 26. Wagner FF, Ladewig B, Angert KS, Heymann GA, Eicher NI, 
Flegel WA. The DAU allele cluster of the RHD gene. Blood 
2002;100:306–11.
 27. Mak KH, Yan KH, Cheng SS, Yuen MY. Rh phenotypes of 
Chinese blood donors in Hong Kong, with special reference to 
weak D antigens. Transfusion 1993;33:348–51.
 28. Wagner T, Körmöczi GF, Buchta C, et al. Anti-D immunization 
by DEL red blood cells. Transfusion 2005;45:520–6.
 29. von Zabern I, Flegel WA. IVS5-38del4 deletion in the RHD 
gene does not cause a DEL phenotype: relevance for RHD 
alleles including DFR-3. Transfusion 2007;47:1552–5.
 30. Yasuda H, Ohto H, Sakuma S, et al. Secondary anti-D immu-
nization by Del red blood cells. Transfusion 2005;45:1581–4.
 31. Körmöczi GF, Gassner C, Shao CP, et al. A comprehensive 
analysis of DEL types: partial DEL individuals are prone to 
anti-D alloimmunization. Transfusion 2005;45:1561–7.
 32. Flegel WA. Response to: Are weak D RBCs really immunogenic? 
(letter). Transfusion 2006;46:1063–4.
 33. Wang QP, Dong GT, Wang XD, et al. An investigation of 
secondary anti-D immunization among phenotypically RhD-
negative individuals in the Chinese population. Blood Transfus 
2014;12:238–43.
 34. Wang M, Wang BL, Xu W, et al. Anti-D alloimmunization in 
pregnant women with DEL phenotype in China. Transfus Med 
2015;25;163–9.
 35. Xu W, Zhu M, Wang BL, et al. Prospective evaluation of a 
transfusion policy of RhD-positive red blood cells into DEL 
patients in China. Transfus Med Hemother 2015;42:15–21.
 36. Gardener GJ, Legler TJ, Hyett JA, et al. Anti-D in pregnant 
women with the RHD(IVS3+1G>A)-associated DEL pheno-
type. Transfusion 2012;52:2016–9.
 37. Wang YH, Chen JC, Lin KT, et al. Detection of RhD(el) in 
RhD-negative persons in clinical laboratory. J Lab Clin Med 
2005;146:321–5.
132 IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017
The editorial staff of Immunohematology welcomes manuscripts 
pertaining to blood group serology and molecular genetics for 
consideration for publication. We are especially interested in 
review articles, case reports, papers on platelet and white cell 
serology, scientific articles covering original investigations or new 
blood group alleles, papers on molecular testing, and papers on 
new methods for use in the blood bank. To obtain instructions for 
submitting scientific articles, case reports, and review articles, 
see Instructions for Authors in every issue of Immunohematology 
or e-mail a request to immuno@redcross.org. Include fax and 
phone numbers and e-mail address with all manuscripts 




Immunohematology is printed on acid-free paper.
For information concerning Immunohematology or the 
Immunohematology Methods and Procedures manual, 
contact us by e-mail at immuno@redcross.org.
D.H. Kwon et al.
 38. Seo MH, Won EJ, Hong YJ, et al. An effective diagnostic 
strategy for accurate detection of RhD variants including Asian 
DEL type in apparently RhD-negative blood donors in Korea. 
Vox Sang 2016;111:425–30.
 39. Ogasawara K, Suzuki Y, Sasaki K, et al. Molecular basis for D– 
Japanese: identification of novel DEL and D-alleles. Vox Sang 
2015;109:359–65.
 40. Gu J, Wang X, Shao C, et al. Molecular basis of DEL phenotype 
in the Chinese population. BMC Med Genet 2014;15:54.
 41. Li Q, Ye LY, Guo ZH, Zhang YX, et al. Molecular basis of D 
variants between Uigur and Han blood donors in Xinjiang. 
Transfus Med 2008;18:199–203.
 42. Wu JJ, Hong XZ, Xu XG, et al. RHD 1227A allele frequency 
among Rh negative population and random population. 
Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:1234–7.
 43. Hoeffel EM, Rastogi S, Kim MO, Shahid H. The Asian 
population: 2010. Suitland, MD: United States Census Bureau, 
2010.
 44. Wu X, Wu D, Wang M, et al. Analysis of frequency of a 
RHD1227A allele in Chinese Hans (abstract). Zhonghua Yi Xue 
Yi Chuan Xue Za Zhi 2014;31:793–6.
 45. Li JH, Zhang CY, Sun LH, Liu J. Molecular mechanisms of 
RhDel phenotype in blood donation population of Chinese 
Harbin area (abstract). Zhongguo Shi Yan Xue Ye Xue Za Zhi 
(Chinese) 2012;20:1478–81.
 46. Chen Q, Li M, Li M, et al. Molecular basis of weak D and DEL 
in Han population in Anhui Province, China (abstract). Chin 
Med J (Engl) 2012;125:3251–5.
 47. Sun CF, Liu JP, Chen DP, et al. Use of real time PCR for 
rapid detection of Del phenotype in Taiwan. Ann Clin Lab Sci 
2008;38:258–63.
 48. Yazer MH, Vassallo R, Delaney M, et al. Trends in age and red 
blood cell donation habits among several racial/ethnic minority 
groups in the United States. Transfusion 2017;57:1644–55.
 49. Yazer MH, Delaney M, Germain M, et al. Trends in US minority 
red blood cell unit donations. Transfusion 2017;57:1226–34
 50. Flegel WA, Castilho SL, Keller MA, et al. Molecular 
immunohematology round table discussions at the AABB 
Annual Meeting, Philadelphia 2014. Blood Transfus 2016; 
14:425–33.
 51. Garratty G. Do we need to be more concerned with weak D 
antigens? Transfusion 2005;45:1547–51.
 52. Denomme GA, Flegel WA. Applying molecular immuno-
hematology discoveries to standards of practice in blood banks: 
now is the time. Transfusion 2008;48:2461–75.
Dong Hyang Kwon, MD, Resident in Pathology (corresponding 
author), Department of Pathology and Laboratory Medicine, 
MedStar Georgetown University Hospital, 3800 Reservoir Road, 
NW, Washington, DC 20007, donghyang.kwon@gunet.georgetown.
edu; S. Gerald Sandler, MD, Professor of Pathology and Medicine, 
Georgetown University School of Medicine, and Medical Director, 
Transfusion Service, Department of Laboratory Medicine, MedStar 
Georgetown University Hospital, Washington, DC; and Willy 
Albert Flegel, MD, Chief, Laboratory Services Section, Department 
of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, and 
Professor of Pathology (adjunct), Georgetown University School of 
Medicine, Washington, DC.
